Categories: Health

GN Store Nord A/S – Notice to convene the Annual General Meeting 2026

GN Store Nord’s Annual General Meeting will be held on Wednesday, March 11, 2026, at 10:00 a.m. CET at the company’s address: Lautrupbjerg 7, 2750 Ballerup, Denmark.

Please find attached the notice to convene the Annual General Meeting, including the agenda and complete proposals.

For further information, please contact:

Investor Relations
Rune Sandager +45 45 75 92 57

Media Relations
Steen Frentz Laursen +45 20 65 34 20

About GN
GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring people closer through the power of sound and vision.

GN was founded more than 150 years ago with a vision to connect the world. Today, we proudly honor that legacy with our world-leading expertise in the human ear, audio, video and speech, wireless technologies, software, miniaturization, and collaboration with leading technology partners. GN’s solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com – and connect with us on LinkedIn, Facebook and X.

GlobeNews Wire

Recent Posts

TTEC Sets New Standard for AI-Driven Frontline Performance with TTEC Perform and TTEC RealSkill

AUSTIN, Texas, Feb. 16, 2026 (GLOBE NEWSWIRE) -- TTEC Holdings, Inc. (NASDAQ: TTEC), a leading…

1 hour ago

UTI GROUP : Nominations et acquisition du groupe MALTEM par ROBINSON TECHNOLOGIES

A la suite de l’Assemblée Générale Extraordinaire qui s’est tenue le lundi 16 février 2026,…

1 hour ago

Transactions in connection with share buyback programme

Company announcement No. 13/2026                                                  16 February 2026 Transactions in connection with share buyback programmeOn…

1 hour ago

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1,…

2 hours ago

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470U.S.…

2 hours ago

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV…

2 hours ago